Targeting lethal minimal residual disease in small cell lung cancer Journal Article
| Authors: | Patel, J.; Krug, L. M.; Azzoli, C. G.; Gomez, J.; Kris, M. G.; Miller, V. A. |
| Article Title: | Targeting lethal minimal residual disease in small cell lung cancer |
| Abstract: | In the last three decades, treatment for small cell lung cancer has improved with advances in chemotherapy and radiotherapy. Almost all patients respond initially to standard chemotherapy, and some patients with limited stage disease are cured with the combination of chemotherapy and thoracic irradiation. Nonetheless, the majority of patients will experience lethal relapse from chemotherapy-resistant micrometastatic disease, and this has resulted in poor long-term survival for most patients. Addressing the problem of relapse requires unique approaches to eliminating minimal residual disease. This review will focus on the detection of minimal residual disease as well as strategies with which to treat it, including matrix metalloproteinase inhibitors, tyrosine kinase inhibitors, and vaccine therapy. Copyright 2003, Elsevier Science (USA). All rights reserved. |
| Keywords: | immunohistochemistry; cancer chemotherapy; cancer survival; unclassified drug; clinical trial; review; cancer recurrence; cisplatin; antineoplastic agents; drug targeting; gemcitabine; paclitaxel; cancer adjuvant therapy; cancer radiotherapy; imatinib; stem cell factor; bcg vaccine; carboplatin; cancer immunotherapy; reverse transcription polymerase chain reaction; protein targeting; etoposide; lung neoplasms; irinotecan; monoclonal antibody; protein tyrosine kinase inhibitor; lung small cell cancer; cancer vaccine; cancer vaccines; ganglioside gd2; diagnostic value; minimal residual disease; neoplasm, residual; enzyme inhibitors; immunogenicity; irradiation; matrix metalloproteinase; immunological adjuvant; protein-tyrosine kinases; ganglioside gm1; toxicity; dna determination; musculoskeletal disease; drug conjugation; ganglioside gd3; ganglioside gm2; marker gene; vaccines; marimastat; keyhole limpet hemocyanin; matrix metalloproteinases; prinomastat; carcinoma, small cell; qs 21; tanomastat; monoclonal antibody bec2; bombesin; antiidiotypic antibody; humans; human; priority journal; fucosylganglioside gm1 keyhole limpet hemocyanin; ganglioside gm2 globo h polysialic acid fucosylganglioside gm1 |
| Journal Title: | Seminars in Oncology |
| Volume: | 30 |
| Issue: | 1 |
| ISSN: | 0093-7754 |
| Publisher: | Elsevier Inc. |
| Date Published: | 2003-02-01 |
| Start Page: | 79 |
| End Page: | 85 |
| Language: | English |
| DOI: | 10.1053/sonc.2003.50018 |
| PUBMED: | 12635092 |
| PROVIDER: | scopus |
| DOI/URL: | |
| Notes: | Export Date: 25 September 2014 -- Source: Scopus |
Altmetric
Citation Impact
BMJ Impact Analytics
Related MSK Work